Session » Abstracts: Reproductive Issues in Rheumatic Disorders (2627–2632)
- 3:00PM-3:15PM
-
Abstract Number: 2627
Risk of Adverse Pregnancy Outcomes in Individuals with Rheumatic Diseases Using Prenatal Antirheumatic Drugs: a Population-Based Cohort Study
- 3:15PM-3:30PM
-
Abstract Number: 2628
Calprotectin and Anti-CCP Antibodies Predict Development of Preeclampsia
- 3:30PM-3:45PM
-
Abstract Number: 2629
Predictors of 30-day Readmissions in Pregnant Patients with Systemic Lupus Erythematosus: The Impact of Social Determinants of Health.
- 3:45PM-4:00PM
-
Abstract Number: 2630
The Absence of DORIS Remission Is Associated with Greater Risk of Preterm Birth and Preeclampsia in SLE Pregnancies
- 4:00PM-4:15PM
-
Abstract Number: 2631
Dapirolizumab Pegol, a Novel CD40L Inhibitor, Showed No Adverse Outcomes in an In Vivo Non-Human Primate Reprotoxicity Study and Displayed Minimal to No Human Placental Transfer in an Ex Vivo Study
- 4:15PM-4:30PM
-
Abstract Number: 2632
Maternal vascular malperfusion: association with adverse perinatal outcomes in lupus pregnancies